{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"7.43","upperLimit":"NA","value":"16.82"},{"comment":"Not reached","groupId":"OG001","lowerLimit":"8.54","upperLimit":"NA","value":"22.34"},{"groupId":"OG002","lowerLimit":"7.46","upperLimit":"14.75","value":"14.75"},{"groupId":"OG003","lowerLimit":"6.51","upperLimit":"25.99","value":"18.43"}]}],"title":"Duration of response from onset of response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.87","upperLimit":"3.98","value":"2.09"},{"groupId":"OG001","lowerLimit":"1.84","upperLimit":"3.98","value":"2.17"},{"groupId":"OG002","lowerLimit":"1.87","upperLimit":"3.71","value":"2.02"},{"groupId":"OG003","lowerLimit":"1.89","upperLimit":"8.44","value":"3.78"}]}],"title":"Time to onset of response from randomization"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"Time from the date of first documented confirmed response (complete or partial response) until the first date of documented progression or death in the absence of disease progression. Complete response (ie., CR) was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \\<10 mm. Partial response (ie., PR) was defined as at least a 30% decrease in the sum of the diameter of TL, taking as reference the baseline sum of diameters.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"MEDIAN","populationDescription":"A subset of FAS subjects who achieve confirmed CR or PR as determined per RECIST 1.1 using Investigator assessment. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"From the date of first documented response until the first date of documented progression or death, assessed until the final analysis DCO (27Aug2021, to a maximum of approximately 46 months).","title":"Duration of Objective Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}